Igene Biotechnology Gross Profit vs. Number Of Employees
Based on the key profitability measurements obtained from Igene Biotechnology's financial statements, Igene Biotechnology may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in April. Profitability indicators assess Igene Biotechnology's ability to earn profits and add value for shareholders.
Check out Risk vs Return Analysis.
For Igene Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Igene Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Igene Biotechnology utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Igene Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Igene Biotechnology over time as well as its relative position and ranking within its peers.
Igene |
Igene Biotechnology Number Of Employees vs. Gross Profit Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Igene Biotechnology's current stock value. Our valuation model uses many indicators to compare Igene Biotechnology value to that of its competitors to determine the firm's financial worth. Igene Biotechnology is rated fourth overall in gross profit category among its peers. It is rated second overall in number of employees category among its peers . The ratio of Gross Profit to Number Of Employees for Igene Biotechnology is about 56,420 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Igene Biotechnology's earnings, one of the primary drivers of an investment's value.Igene Number Of Employees vs. Gross Profit
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Igene Biotechnology |
| = | 1.02 M |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Igene Biotechnology |
| = | 18 |
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
Igene Number Of Employees vs Competition
Igene Biotechnology is rated second overall in number of employees category among its peers. The total workforce of Materials industry is currently estimated at about 11,544. Igene Biotechnology adds roughly 18.0 in number of employees claiming only tiny portion of all equities under Materials industry.
Igene Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Igene Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Igene Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Igene Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Igene Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Igene Biotechnology, Inc. focuses on the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. IGENE Biotechnology, Inc. was founded in 1981 and is based in Columbia, Maryland. IGENE BIOTECHNOLOGY operates under Agricultural Inputs classification in the United States and is traded on PNK Exchange. It employs 18 people.
Igene Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Igene Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Igene Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Igene Biotechnology's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Igene Biotechnology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run CEOs Directory Now
CEOs DirectoryScreen CEOs from public companies around the world |
| All Next | Launch Module |
Use Investing Themes to Complement your Igene Biotechnology position
In addition to having Igene Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Heavy Metals Thematic Idea Now
Heavy Metals
Companies involved in mining, production, and distribution of various industrial metals and minerals. The Heavy Metals theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Heavy Metals Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Igene Pink Sheet
To fully project Igene Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Igene Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Igene Biotechnology's income statement, its balance sheet, and the statement of cash flows.